Last edition
News about "Remigromig DME treatment"
Merck's Remigromig Targets Wnt Pathway in Eye Disease
Merck’s remigromig meets the primary endpoint in the phase 2b/3 BRUNELLO study in adults with Diabetic Macular Edema (DME).
Remigromig DME Treatment | 25/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members